Achieving breakthroughs in healthcare requires constant attention to ensure care evolves alongside the people who rely on it. At Pfizer, we know that global health challenges are too great for any one company or organization to solve alone; to tackle them, we must coordinate tools and minds around the world, including from outside our own walls. Too often, innovations with the potential to change lives face roadblocks not because they lack promise but because innovators may not have access to the resources that can help them live up to their potential. Our decades-long expertise in investment and acquisition has focused on breakthrough products that strategically grow our portfolios, giving us a unique opportunity to identify promising medicines and help ensure more patients in need can access them as we grow.

In recent years, Pfizer’s investments have supported innovation and product evolution, including preparation for potential approvals and product launches, and support for clinical trials. We are committed to strategically capitalizing on growth opportunities, primarily by advancing our own product pipeline and maximizing the value of our existing products, but also through various business development activities. We view our business development activity as an enabler of our strategies and seek to generate growth by pursuing opportunities and transactions that have the potential to strengthen our business and our capabilities. We assess our business, assets and scientific capabilities/portfolio as part of our regular, ongoing portfolio review process and also continue to consider business development activities that will help advance our business strategy.

We are committed to collaboration, with currently 40% of our portfolio externally sourced or enabled through partnerships at all stages of clinical and technological development and ongoing business development. In October 2022, Pfizer acquired both Biohaven Pharmaceutical Holding Company Ltd. (Biohaven), a clinical-stage biopharmaceutical firm investigating new therapies for neurological conditions, and Global Blood Therapeutics (GBT), a company focused on the discovery, development and delivery of treatments for people living with sickle cell disease (SCD).

A key part of Pfizer’s acquisition of Biohaven was its innovative migraine therapy, rimegepant. Approved for both acute treatment and prevention of episodic migraine in adults, rimegepant is part of a portfolio of promising calcitonin gene-related peptide (CGRP) assets and an ongoing example of Pfizer’s patient-focused investment. Pfizer’s acquisition of Biohaven is part of our long-term work in pain and women’s health, and continued momentum from a 2021 strategic collaboration for the commercialization of rimegepant outside the U.S. Through access to Primary Care Physicians, specialists and health systems, Pfizer can support people living with migraine when they most need it. Our ongoing commitment to rimegepant’s global success has helped bring an innovative new treatment option to the millions of patients around the world who live with migraine.

Pfizer’s acquisition of GBT brings a portfolio and pipeline that has the potential to address the full spectrum of critical needs for the underserved SCD community, reinforcing Pfizer’s commitment to SCD and building on a 30-year legacy in the rare hematology space. With GBT’s talent, portfolio and pipeline now a part of the company, combined with the deep market knowledge and insights Pfizer has built along with its leading scientific and clinical capabilities, this acquisition will help accelerate innovation as we aim to bring potential breakthrough treatments to the SCD community as quickly as possible.

By providing access to global resources and scientific and market expertise, Pfizer helps ensure continuity of promising products and programs across industries, sectors and stakeholders. Our sustained success in supporting products through partnership and acquisition addresses some of the most diverse healthcare needs in the industry and cements Pfizer’s role as a leader in areas including oncology, neurology, vaccines and antimicrobial resistance. With the expertise, capabilities and reach of an international biopharmaceutical company and the entrepreneurial spirit of a nimble biotech, we are uniquely positioned to help accelerate the next era of innovation through cutting-edge science and business reimagination.